The availability, cost and affordability of essential medicines for asthma and COPD in low- and middle-income countries: A systematic review
M. Stolbrink (Liverpool, United Kingdom), H. Thomson (London, United Kingdom), R. Hadfield (Sydney, Australia), O. Ozoh (Lagos, Nigeria), R. Nantanda (Kampala, Uganda), S. Jayasooria (Sheffield, United Kingdom), B. Allwood (Cape Town, South Africa), D. Halpin (Exeter, United Kingdom), S. Salvi (Pune, India), M. Montes De Oca (Caracas, Venezuela), K. Mortimer* (Liverpool, United Kingdom), S. Rylance* (Geneva, Switzerland)
Source: International Congress 2022 – Chronic airway diseases and infections: management and prevalence
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Stolbrink (Liverpool, United Kingdom), H. Thomson (London, United Kingdom), R. Hadfield (Sydney, Australia), O. Ozoh (Lagos, Nigeria), R. Nantanda (Kampala, Uganda), S. Jayasooria (Sheffield, United Kingdom), B. Allwood (Cape Town, South Africa), D. Halpin (Exeter, United Kingdom), S. Salvi (Pune, India), M. Montes De Oca (Caracas, Venezuela), K. Mortimer* (Liverpool, United Kingdom), S. Rylance* (Geneva, Switzerland). The availability, cost and affordability of essential medicines for asthma and COPD in low- and middle-income countries: A systematic review. 2420
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|